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1 GENERAL PART 
1.1 INTRODUCTION 
1.1.1 Designer Drugs  
Chirality and differences in pharmacodynamic and pharmacokinetic properties of the 
enantiomers is not restricted to legal drugs such as ketamine, omeprazole, or 
citalopram. Drugs of abuse can also contain chiral centers and the respective 
enantiomers might also differ in their properties. As consumption of drugs of abuse is 
a widespread problem in societies all over the world and the abused compounds are 
not investigated before appearance on the illicit drug market, knowledge about 
possible differences of their enantiomers is very limited. Especially, so-called 
designer drugs are more and more popular among young people. The most 
frequently abused drugs are amphetamine-derived designer drugs which are chiral 
compounds containing an asymmetric carbon atom in the side chain. One class of 
amphetamine-derived designer drugs are the methylenedioxy derivatives 3,4-
methylene¬dioxymethamphetamine (MDMA, Ecstasy, Adam), 3,4-methylene-
dioxy¬ethylamphetamine (MDEA, Eve), N-methyl-benzodioxolyl-butanamine (MBDB, 
Eden), 4-methylenedioxy-amphetamine (MDA), and benzodioxolyl-butanamine 
(BDB). Their chemical structures are shown in Fig. 1.  
 
1.1.2 Metabolism 
As shown in Fig. 1, in vivo studies of MDMA, MDEA, and MBDB revealed two main 
metabolic steps: N-demethylation and demethylenation. The first pathway, 
predominant in humans, involves cytochrome p450 (CYP)-catalyzed O-
demethylenation to the corresponding 3,4-dihydroxy compounds followed by 
catechol-O-methyltransferase (COMT)-catalyzed O-methylation to the 4-hydroxy-3-
methoxy metabolites and O-conjugation with sulfate or glucuronic acid. The second 
entails initial N-dealkylation to MDA or BDB followed by deamination and oxidation to 
the corresponding benzoic acid derivatives conjugated with glycine.1-3 Urinary 
recovery of MDMA represents about 15% which indicates that the drug is mainly 
 eliminated by metabolism.3 MDA and BDB can also undergo O-demethylenation to 
the 3,4-dihydroxy compounds following O-methylation and O-conjugation with 
glucuronic acid or sulfate. The catechols, formed via metabolic demethylenation of 
the aforementioned drugs, can easily be oxidized to their corresponding ortho-
quinones which in turn can form adducts with glutathione and other thiol-containing 
compounds.4,5 
 
 
 
Fig. 1: Chemical structures and main metabolic steps of the studied amphetamine-
derived designer drugs 
1.1.3 Pharmacology and Toxicology 
MDMA, MDEA, and MBDB have effects on the central nervous system described as 
altered state of consciousness, well being, increased tactile sensations, and a strong 
desire to socialize.6,7 Additionally, they can increase the concentration of dopamine, 
serotonin, and noradrenaline in the central nervous system. MDA itself is reported to 
be twice as potent as MDMA and MDEA.7 However, BDB should have similar 
 pharmacological properties as the related aforementioned compounds. Therefore, 
they are all members of the same drug class called “entactogens”.8  
Different pharmacokinetic properties were described for MDMA, MDEA, and MDA 
enantiomers.9-14 Johnson et al. reported about differences in the dose response 
curve and for changes in serotonergic function and neurotoxicity between S-(+)-MDA 
and R-(-)-MDA.15 Several studies have shown that there is a metabolic preference for 
the S-enantiomer of MDMA.9-14 MDEA was investigated concerning enantioselective 
pharmacokinetics in vivo16,17 and the plasma half life of R-MDEA was found to be 
longer than that of S-MDEA. Accordingly, the plasma concentrations of the S-
enantiomers of the main metabolites N-ethyl-4-hydroxy-3-methoxyamphetamine 
(HMEA) and MDA were much higher than those of the R-enantiomers. 
Enantioselective pharmacokinetics of MDEA resulting in higher plasma 
concentrations of R-MDEA were also confirmed by other authors.12,18,19 
Concerning chronic toxicity, data strongly suggest that adducts of the catecholic 
metabolites of MDMA, MDEA, MBDB, and MDA can cause irreversible damage to 
serotonergic nerve terminals in the central nervous system and systemic metabolism 
may play a role in their neurotoxicity.3,9,20-27 This was concluded from the observation 
that direct injection of ecstasy into the brain fails to reproduce the neurotoxic effects 
seen after systemic administration,28 and from the report that alteration of CYP-
mediated MDMA metabolism influences MDMA induced neurotoxicity.28,29 
Metabolites such as DHMA are easily be oxidized to their corresponding quinones 
which can form adducts with glutathione and other thiol-containing compounds.4,30,31 
Recently, such adducts have been implicated in MDMA neurotoxicity.32,33 Only few 
publications are available on the neurotoxicity in living humans. In these studies, 
recreational MDMA users were found to have decreased levels of 5-
hydroxyindoleacetic acid, the main metabolite of serotonin, in the cerebrospinal 
fluid34 and a reduced density of serotonin transporters in the brain as determined by 
positron emission computed tomography with a ligand selective for these 
transporters.35 Both findings are indicative of serotonin neurotoxicity in humans. 
Unfortunately, these studies were performed with recreational users, so it cannot be 
excluded whether the reported findings might also be due to use of other recreational 
drugs especially since polydrug use is not uncommon.  
 1.1.4 Metabolizing Enzymes 
1.1.4.1 Cytochrome P450 
In general, drugs are metabolized by a variety of enzymes, producing metabolites 
that are usually less toxic than their parent compounds. The formed metabolites may 
also be more reactive, producing toxic effects. CYP enzymes are responsible for 
oxidative and, to a minor extent, reductive metabolic transformations of drugs, 
environmental chemicals and natural compounds. Over its long history of more than 
3.5 billion years, the CYP superfamily of enzymes has developed remarkable 
versatility. As shown in figure 2, the primary catalytic function of CYPs was identified 
as transfer of one oxygen atom from molecular oxygen into various substrates. A 
coenzyme, cytochrome P450 oxidoreductase (OR), is essential for CYP catalytic 
function, and cytochrome b5 can stimulate catalytic activities of some enzymes.36  
 
 
Fig. 2: The cytochrome P450 redox cycle. 
Single electron shifts are frequently responsible for the formation of reactive 
intermediates or allow the leakage of free radicals capable of causing toxicity. When 
 a CYP enzyme activity is modified by induction or inhibition, the biological activity of 
the xenobiotic substrate can be altered considerably. Such effects are called drug-
drug, drug-chemical or chemical-chemical-interactions. Such interactions can modify 
the disposition of xenobiotics.37-39 In mammals, the enzymes can be identified in 
nearly every tissue, being most abundantly present in the liver. The CYP superfamily 
has been classified in different families in accordance to the degree of homology of 
amino acid sequence in their protein structures. CYP enzymes having ≤ 40% 
homology in their amino acid sequence are classified in different families which are 
designated by Arabic numbers, for example, CYP1. Each family is further divided into 
subfamilies of enzymes. The enzymes within a mammalian subfamily have ≥ 55% 
sequence homology and are designated by capital letters, for example, CYP1A. An 
Arabic number is used for designating individual enzymes within a subfamily, for 
example, CYP1A2.37 In humans, 18 CYP families with 43 subfamilies and 57 CYP 
isoenzymes are known so far, of which only 3 families with 7 subfamilies and 12 CYP 
isoenzymes are relevant for drug metabolism,40 namely CYP1A1, CYP1A2, CYP2A6, 
CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP3A4, 
and CYP3A5.41  
Human liver-derived enzyme preparations, e.g. human liver microsomes (HLM) 
contain a natural mixture of CYPs. Chemical inhibitors, immunochemical inhibitors, 
and/or correlation analyses with marker activities must be used to obtain information 
on which enzymes are performing specific biotransformations. In contrast, only a 
single active CYP is present in preparations of cDNA-expressed enzymes. Inhibitors 
and correlation analyses are not needed, because the mentioned assignments can 
be performed by direct incubation of the drug with a panel of individual CYPs. 
However, the balance of enzymes, present in vivo, is lost.36 Bacteria, yeast, 
baculovirus and several mammalian cells have been used to produce a wide range of 
catalytically active CYPs. The baculovirus system offers high-level expression of both 
the CYP and OR, and are therefore advantageous for metabolism studies of all 
kinds, especially for low turnover substrates. The development of the cDNA-bearing 
virus is relatively time-consuming and labor-intensive, but baculovirus infected insect 
cell microsomes are commercially available. However, because the enzymes are 
produced transiently in the insect host cells, exact harvest time can have a 
pronounced effect on the activity of the final preparation.42  
 
 1.1.4.2 Catechol-O-methyltransferase 
Julius Axelrod, an American biochemist (1912-2004), whose Nobel Prize-winning 
research grew out of work done by Euler, specifically Euler’s discovery of 
noradrenaline (norepinephrine). Axelrod, in turn, discovered that noradrenaline could 
be neutralized by an enzyme, catechol-O-methyltransferase (COMT, EC 2.1.1.6), 
which he isolated and named.  
In either rats or humans, there is only one single gene for COMT, encoding the 
soluble COMT (S-COMT) and the membrane-bound COMT (MB-COMT) by using 
two separate promoters.43,44 In most human tissues, the majority of COMT is present 
in the soluble form (S-COMT). However, in human brain, 70% of the total COMT 
proteins was found to be MB-COMT and 30% of them S-COMT. Analyses with 
overexpressed MB-COMT showed that it is mainly located in the rough endoplasmic 
reticulum, facing the cytoplasm, and no MB-COMT is present in the cytoplasmic 
membrane. The overexpressed S-COMT in cultured cells was found to be localized 
in cytosol and nucleus.45,46  
These enzymes proved critical to an understanding of the entire nervous system 
because they catalyze the enzymatic O-methylation of endogenous catecholamines 
and other catechols.47 The physiological substrates of COMT include catecholamines 
(dopamine, norepinephrine, and epinephrine), catechol estrogens, and many others. 
In addition, many drugs, such as dobutamine, isoprenaline, levodopa, and 
benserazide are also substrates of COMT.48-51 A few recent studies demonstrated 
that several dietary phytochemicals such as bioflavonoids and tea catechins are 
exceptionally good substrates for the COMT-mediated O-methylation with metabolic 
rates much higher than endogenous catecholamines and catechol estrogens.52-55 
COMT has also been suggested to have additional important physiological functions 
in organs like the kidney and intestine through modulating the rate of dopamine 
metabolism which should also be true in the brain. COMT may modulate the 
neurotransmitter functions of dopamine and norepinephrine altering the rate of their 
metabolic inactivation.56 
 
As depicted in Fig. (3), COMT catalyzes the transfer of the methyl group from S-
adenosylmethionine (SAM) to one of the two hydroxyl groups of the catechol 
substrates in the presence of Mg2+ as a cofactor.49 
  
 
Fig. 3: Schematic illustration of the catalytic mechanism of S-COMT-mediated O-methylation. 
The dotted lines indicate the possible non covalent interactions between the molecules or atoms. 
 
The binding of Mg2+ to the COMT protein improves the ionization of the two hydroxyl 
groups of the catechol substrate. The lysine residue (Lys144) accepts the proton of 
one of the two hydroxyl groups, acting as a catalytic base for the nucleophilic methyl 
transfer reaction. An earlier study suggested that the methyl transfer proceeds 
through a direct nucleophilic attack by one of the hydroxyl groups of the catechol 
substrate at the methyl carbon of SAM in a tight SN2-like transition state.57,58 
Nevertheless, there are also a number of S-COMT and MB-COMT characteristics for 
the O-methylation of different catechols in vitro. First, S-COMT generally has much 
higher apparent KM values (lower affinity) for various substrates than MB-COMT 
(higher affinity).59,60 Second, despite the generally low affinities of S-COMT for 
various substrates, its overall catalytic capacity (Vmax) is ten to one hundred folds 
higher than values for the MB-COMT. Third, for the O-methylation of catecholamines, 
both S-COMT and MB-COMT favor 3-O-methylation (meta-position) over 4-O-
methylation (para-position). It appears that MB-COMT is even more regioselective 
than S-COMT in favor of 3-O-methylation.61 The reason for the favorable 3-O-
methylation over 4-O-methylation may be as follows. While the 4-O-hydroxyl group of 
the substrate approaches SAM, its side chain is forced to be orientated in an 
unfavorable position towards a cluster of hydrophobic amino acid residues located at 
or near the catalytic site (see Fig. 3). Molecular dynamic simulation studies appeared 
to be in agreement with this explanation.62,63 
 Val158Met is one single nucleotide polymorphism in the gene that codes COMT. This 
single nucleotide substitution between G and A results in an amino acid change from 
valine to methionine at codon 158 and provides a higher activity of the enzyme. It 
was recently associated with modulation of cognition and diseases like 
schizophrenia.64 
Characterization of the human enzymes involved in the metabolism of specific drugs 
is becoming increasingly important. Such characterization should consider two 
processes involving the new drug: metabolism and inhibition. The characterization of 
enzymes involved in metabolism of a new drug allows prediction, based on 
knowledge of the ability of co-administered drugs to inhibit the same enzymes, of 
which co-administered drugs may inhibit the metabolism of the new drug. This 
information can also be used to predict individual variability based on known 
metabolic polymorphisms.36 However, also the new drug can act as an inhibitor what 
may lead to interactions with co-administered drugs. 
 
1.1.5 Preparation of Single Enantiomers  
1.1.5.1  Separation of racemic MDMA, MDEA, and MBDB 
MDMA, MDEA, and MBDB were separated using a Hewlett Packard Series 1050 
semi-preparative HPLC system consisting of a pump and a variable wavelength 
detector (λ = 263 nm for MDMA and MDEA and λ = 285 nm for MBDB) which was 
coupled to an Advantec SF 2120 Super Fraction collector. The stationary phase was 
a Merck Hibar HPLC ChiraDex column (250 x 10 mm, 5 µm). The mobile phase 
varied in dependence of the separated racemic mixture to obtain best separation. 
The respective conditions are given in Table 1. Analytes were separated in aliquots 
(100 µl, MDMA and MDEA; 250 µl, MBDB) of an aqueous stock solution (5 mg/ml 
MDMA and MDEA; 1 mg/ml, MBDB). In total, 40 mg MDMA, 30 mg MDEA, and 50 
mg MBDB were separated. Fractions were collected and checked for optical purity. 
Therefore, 10 µl of the respective fraction was transferred to 1.5 ml reaction caps and 
diluted with 200 µl aqueous carbonate buffer (35 g/l sodium bicarbonate and 15 g/l 
sodium carbonate, pH 9). Purity was checked by gas chromatography-mass 
spectrometry (GC-MS) as described in detail under sample preparation for purity 
check. 
  
 mobile phase A mobile phase B flow rate pH and temperature 
R,S-MDMA 0.1 M ammonium 
acetate buffer 85% 
acetonitrile 15% 3 ml/min pH 6.5 at 8°C 
R,S-MDEA 0.1 M ammonium 
acetate buffer 85% 
acetonitrile 15% 3 ml/min pH 6.5 at 8°C 
R,S-MBDB 0.1 M ammonium 
acetate buffer 85% 
15% mobile phase B 
(acetonitrile 49.5%, 
methanol 49.5%, and 
triethylamine 1%), 
2 ml/min pH 7.0 at 15°C 
 
Tab. 1: HPLC conditions for separation of the racemic mixtures. 
 
For isolation of MDMA enantiomers from the collected fractions, the acetonitrile part 
of the HPLC solvent was evaporated. The remaining part was acidified with 1 ml 
0.01 mol/L HCl and the enantiomers were isolated from the aqueous part by solid 
phase extraction (SPE) using Varian Bond Elut SCX HF cartridges (5 g, 20 ml), 
previously conditioned with 10 ml of methanol and 10 ml of water. After passage of 
the fractions, the cartridges were washed with 10 ml of 0.01 mol/L hydrochloric acid 
and 10 ml of methanol. The compounds were eluted twice with 10 ml freshly 
prepared mixture of methanol/aqueous ammonia (96:4 v/v). The eluates were 
evaporated to dryness under reduced pressure and reconstituted in 1.0 ml 0.01 mol/L 
HCl and quantified according to ref.13 Forty mg of racemic MDMA-HCl were 
separated under the described conditions.  
For MDEA, the fractions containing the separated enantiomers were collected and 
the enantiomers were isolated from the aqueous part by liquid/liquid extraction at pH 
9 using ethyl acetate (three times using 150 ml each). The extracts were evaporated 
to dryness using a Rotavapor under reduced pressure and reconstituted in 1.0 ml of 
0.01 M HCl. Thereafter, the concentrations of the MDEA enantiomers in the resulting 
solution were determined according to the sample preparation and purity check 
section. 
For MBDB, the respective enantiomer fractions were adjusted to pH 12 with sodium 
hydroxide and extracted three times with ethyl acetate (150 mL). The combined 
extracts were dried using magnesium sulfate. Afterwards they were concentrated to a 
volume of approximately 1 mL under reduced pressure. Finally, the amount and 
 purity of the MBDB enantiomers were checked as described in detail under sample 
preparation. Fifty mg of racemic MBDB were separated under the described 
conditions. As the chiral HPLC method did not provide a satisfying purity and 
separation of the enantiomers, the above described separation and extraction 
procedure was performed twice. 
Various buffers and buffer concentrations as well as organic modifiers were tested for 
semi-preparative isolation of the single enantiomers for these experiments. The best 
result in enantiomer separation was achieved with KH2PO4 0.1 mol/L/acetonitrile 95/5 
with triethylamine (TEA) 0.1% but the TEA content as well as the phosphate buffer 
turned out to be problematic in the following isolation of the enantiomers by SPE. The 
conditions described above were finally preferred because they yielded sufficient 
separation combined with favorable properties for further workup. The final products 
were obtained as yellowish powders or aqueous solution of high optical purities. 
Despite rather low recoveries (MDMA ~ 60%, MDEA ~ 75%, MBDB ~ 40% per 
enantiomer), the isolated amounts were sufficient for further kinetic studies. 
 
1.1.5.2 Sample preparation and purity check using GC-MS 
Derivatization was performed according to Peters et al.,13 with slight modifications: 
after adding 20 µl derivatization reagent (0.1 mol/l S-HFBPCl in dichloromethane), 
the reaction vials were sealed and left on a rotary shaker at ambient temperature for 
30 min. After addition of 100 µl cyclohexane to the reaction vials, they were resealed, 
and placed on a rotary shaker for 5 min. After phase separation by centrifugation 
(10000 g for 1 min), the cyclohexane phase was transferred to autosampler vials. 
Aliquots of 3 µl were injected into the GC-MS.  
The samples were analyzed by an Agilent Technologies (AT) 6890 Series GC 
system combined with an AT 5973 network mass selective detector, an AT 7683 
series injector, and an AT enhanced Chem Station G1701CA, version C.00.00 21-
Dec-1999. For detection of MDMA, MDEA, MBDB enantiomers and the internal 
standard MDA-d5, the GC conditions were as follows: splitless injection mode; 
column, 5% phenyl methyl siloxane (HP-5MS; 30 m x 0.25 mm (i.d.); 250 nm film 
thickness); injection port temperature, 280°C; carrier gas, helium; flow rate, 1 ml/min; 
column temperature. 
For separation and detection of MDMA, MDEA, and MBDB the oven and MS 
conditions were as follows: 
 100°C increased to 200°C at 30°C/min, to 260°C at 5°C/min, and to 310°C at 
30°C/min. The negative-ion chemical ionization (NICI)-MS conditions were as 
follows: transfer line heater, 280°C; NICI, methane (2 ml/min); source temperature, 
150°C; solvent delay, 11 min; selected-ion monitoring (SIM) mode with the following 
ions: m/z 432 for MDA-d5 m/z 446 for MDMA and 460 for MDEA and MBDB. For 
separation of MBDB, the GC conditions were modified as follows: 100°C increased to 
221°C at 50°C/min, to 240°C at 4°C/min, and to 310°C at 50°C/min. Solvent delay, 2 
min; Enantiomers were quantified by comparison of their peak-area ratios 
(enantiomers of analyte vs corresponding enantiomer of the IS) to calibration curves 
in which the peak-area ratios of enriched calibrators had been plotted vs their 
concentrations using a weighted (1/x) least-squares linear regression model. 
 1.2 AIMS AND SCOPES 
Some ring substituted amphetamines (RSA) were shown to be metabolized (in vitro 
and in vivo) more or less enantioselectively.9-14 Therefore, elucidating this 
phenomenon is important from the toxicological and pharmacological point of view. 
Concerning the most popular RSA MDMA, several studies have shown that there is a 
metabolic preference for the S-enantiomer9-14 and that this difference might be 
attributable to cytochrome P450 CYP2D6.65-67 MDEA was also investigated 
concerning enantioselective pharmacokinetics in vivo16,17 and the plasma half life of 
R-MDEA was found to be longer than that of S-MDEA. In the case of MBDB, the data 
currently available give no idea whether the S-form of this RSA is also metabolized 
preferably by CYP isoforms. Neither systematic in vivo nor in vitro studies are 
available concerning the CYP-dependent metabolism of MDMA, MDEA, and MBDB 
enantiomers with respect to all relevant isoforms. Only studies using racemic 
mixtures and CYP inhibition in pooled human liver microsomes are available.2 In the 
case of MDA and BDB, the data currently available provide no information on 
whether the S-forms of these RSA are also metabolized preferably by CYP isoforms. 
Neither in vivo nor in vitro studies are available concerning the CYP-dependent 
metabolism of their enantiomers. In addition, it should be of interest to see whether 
theses compounds, considered as MDMA, MDEA, or MBDB metabolites, are 
eliminated enantioselectively.  
Additionally, the question arose whether the primary catecholic metabolites of 
MDMA, MDEA, and MBDB are further methylated with a preference for the S-form. 
This might help to further explain the pharmacokinetic difference between the 
respective enantiomers and whether there are differences in the catalytic behavior 
between S-COMT and MB-COMT. Besides this, an inhibition potential of the 
catechols towards the COMT should be checked as it is known, that MDMA is a 
mechanism based inhibitor of CYP2D6.68 
 Therefore, the aims of the presented studies were: 
 
- To obtain enantioselective enzyme kinetic data of MDMA, MBDB, and MDEA 
demethylenation and dealkylation by the ten CYPs most relevant in human drug 
metabolism  
 
- To obtain enantioselective enzyme kinetic data of the demethylenation of their 
metabolites MDA and BDB  
 
- To obtain enantioselective enzyme kinetic data of the methylation of their 
metabolites DHMA, DHEA, and DHMBB  
 
- Determination of the inhibition potential of DHMA, DHEA, and DHMBB on COMT 
2 PUBLICATIONS OF THE RESULTS 
The results of the studies were published in the following papers: 
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(DOI: 10.1016/J.TOXLET.2009.06.866) 
  
2.5 ENANTIOSELECTIVITY IN THE METHYLATION OF THE CATECHOLIC PHASE-I 
METABOLITES OF METHYLENEDIOXY DESIGNER DRUGS AND THEIR 
CAPABILITY TO INHIBIT COMT CATALYZED DOPAMINE 3-METHYLATION73 
(DOI: 10.1021/TX900134E) 
 
3 CONCLUSIONS 
The studies presented here provided systematic data on the involvement of 
cytochrome P450 isozymes in the metabolism of methylenedioxy designer drugs 
MDMA (Ecstasy), MBDB (Eden), and MDEA (Eve) with respect to their chirality. 
Additionally, it was shown that these drugs are N-dealkylated and demethylenated 
enantioselectively with a preference for the S-enantiomer.69-71 Differences in the 
enantioselectivity of the involved isoforms where observed, indicating CYP2C19 to 
be the most selective in all cases. Furthermore, their N-dealkyl metabolites MDA, 
BDB are also demethylenated with a preference for their S-enantiomers, but these 
primary amines are not metabolized as enantioselectively as the secondary 
amines.72 The catecholic phase-I metabolites of the aforementioned designer drugs 
were investigated for enantioselective methylation and their S-enantiomer were also 
shown to be preferablely formed.73 Inhibition studies performed with DHMA, DHEA, 
and DHMBB clearly indicated an uncompetitive inhibition of the COMT catalyzed O-
methylation of dopamine.73 
These findings must be considered when trying to estimate the time of ingestion from 
drug enantiomer ratios in plasma10,12 because the time course of such ratios might be 
considerably different in CYP2D6 poor metabolizers or in case of inhibition of 
CYP2D6 by co-ingested drugs. In addition, it must be considered that correlation of 
the presented in vitro data with the in vivo situation is not straightforward, because in 
vivo the formed metabolites are further metabolized by O-methylation and/or 
glucuronidation/sulfation. Enantioselectivity of these phase II reactions might of 
course also influence the enantiomer ratios in plasma samples. Considering these 
findings along with the fact that demethylenation is the major metabolic step in vivo, 
the different pharmacokinetic properties of the enantiomers are therefore most likely 
attributable to enantioselective demethylenation by CYP2C19, CYP2D6, and 
CYP3A4. CYP2D6 should be most important in this context, because it is the most 
abundant concerning net clearance at plasma concentrations observed in 
recreational users. 
Concerning the catecholic metabolites, in the author’s opinion, a part of the described 
neurotoxicity of the methylenedioxy designer drugs3,9,20,26,27 could be explained by 
inhibition of the dopamine methylation in the central nervous system (CNS). As 
 MDMA and related drugs are able to increase the concentration of dopamine and 
other neurotransmitters in the CNS8 and as they additionally could inhibit the 
inactivation of these compounds, the described dopamine induced neurotoxicity 
might be enhanced.74 This might be one reason for the drug-induced irreversible 
damage to central nerve terminals. 
 
4 SUMMARY 
In the presented studies, the CYP dependent, enantioselective N-dealkylation and 
demethylenation of the designer drugs MDMA (Ecstasy), MBDB (Eden), and MDEA 
(Eve) was investigated. Furthermore, the COMT-catalyzed O-methylation of the 
supposed neurotoxic catecholic metabolites of the aforementioned drugs and the 
demethylenation of the dealkyl metabolites MDA and BDB was studied. The data 
clearly indicated a metabolic preference for the S-enantiomer of all investigated 
compounds, indicating CYP2C19 to be the most selective in all cases. Furthermore, 
their N-dealkyl-metabolites MDA, BDB are also demethylenated with a preference for 
their S-enantiomers. Data also suggest that the primary amines are not metabolized 
as enantioselectively as the secondary amines. The catecholic phase-I metabolites 
are also enantioselectively methylated with a preference for their S-enantiomer. 
These findings explain in part the observed different in vivo kinetic of these 
methylenedioxy designer drugs. Inhibition studies with the catecholic phase-I 
metabolites DHMA, DHEA, and DHMBB indicated an uncompetitive inhibition of the 
sCOMT catalyzed dopamine 3-methylation. This inhibition of the dopamine 
methylation in the central nervous system could be another reason for the drug-
induced irreversible damage to central nerve terminals. 
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6 ABBREVIATIONS 
MDMA 3,4-methylenedioxymethamphetamine 
MDEA 3,4-methylenedioxyethylamphetamine 
MBDB N-methyl-benzodioxolyl-butanamine 
MDA 3,4-methylenedioxyamphetamine 
BDB benzodioxolyl-butanamine 
CYP cytochrome p450 
COMT catechol-O-methyltransferase 
sCOMT soluble form of catechol-O-methyltransferase 
mbCOMT membrane bound form of catechol-O-methyltransferase 
HMEA  N-ethyl-4-hydroxy-3-methoxyamphetamine 
DHMA 3,4-dihydroxymethamphetamine 
DHEA 3,4-dihydroxyethylamphetamine 
DHMBB 1,2-dihydroxy-4-[2-(methylamino)butyl]benzene 
OR oxidoreductase 
cDNA copy deoxyribonucleic acid 
SAM S-adenosylmethionine 
HPLC high pressure (performance) liquid chromatography 
TEA triethylamine 
S-HFBPCl S-heptafluoroproline chloride 
MS mass spectrometry 
NICI negative ion chemical ionization 
SIM selective ion monitoring 
CNS central nervous system 
RSA ring substituted amphetamines 
 GC gas chromatography 
SPE solid phase extraction 
 
7 ZUSAMMENFASSUNG 
Im Rahmen dieser Dissertation wurde die Cytochrom P450 abhängige, 
enantioselektive N-Desalkylierung und Demethylenierung der Missbrauchsdrogen 
MDMA, MBDB und MDEA untersucht. Des Weiteren wurden Studien zur COMT-
katalysierten O-Methylierung der catecholartigen Phase I Metabolite DHMA, DHEA 
und DHMBB sowie der Demethylenierung der N-Desalkyl-Metaboliten MDA und BDB 
angeschlossen. Die erhaltenen Daten dokumentieren eindeutig eine Präferenz für 
das S-Enantiomer der jeweiligen Stammverbindungen. Das Isoenzym CYP2C19 
scheint in diesem Zusammenhang dasjenige Isoenzym mit der größten 
Enantioselektiviät zu sein. Die N-Desalkyl-Metaboliten der Ausgangsverbindungen 
wurden ebenfalls enantioselektiv, mit einer S-Präferenz, demethyleniert. Es war 
jedoch augenfällig, dass die Enantioselektivität bei diesen primären Aminen niedriger 
zu sein scheint als bei den sekundären Aminen. Auch die catecholartigen Phase I 
Metabolite der zuvor erwähnten Drogen unterliegen einer die S-Enantiomere 
bevorzugenden O-Methylierung. Diese Befunde können auch dazu beitragen, die in 
vivo beobachteten pharmakokinetischen Unterschiede der jeweiligen Enantiomere zu 
erklären. Abschließend wurden Hemmstudien mit den Metaboliten DHMA, DHEA und 
DHMBB durchgeführt. Diese zeigten eine nichtkompetetive Hemmung bezüglich der 
sCOMT-katalysierten 3-O-Methylierung von Dopamin. Diese Hemmung der 
physiologischen Methylierung könnte mit ein Grund für die beschriebene 
drogeninduzierte, irreversible Schädigung der Nervenzellendigungen sein. 
 
